Exhibit 10.1
[***] represents redacted information
OTHER TRANSACTION FOR RESEARCH
BETWEEN
NRX Defense Systems, Inc*.*
1666 Kennedy Causeway, Ste 612,
North Bay Village, Fl 33141
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
675 NORTH RANDOLPH STREET
ARLINGTON, VA 22203-1714
CONCERNING
Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS)
Agreement No.: HR0011-26-3-E138
Purchase Requisition No.: HR0011687084
Total Amount of the Agreement: $11,177,757.37
Funds Obligated: $6,681,753.00
Authority: 10 U.S.C. § 4021
Line of Appropriation:
| CLIN/SUBCLIN | ACRN | Accounting Line | CIN | Amount |
| 0001/000101 | AA | ^^^097^2026^2027^^0400^000^^255^D^0602024E^^^^^1300^00008522^012199^DARPA^DSO - DEFENSE SC^DSTRJJ^2026.WP-01.CORE.^255.00 R&D Cont^^^ | HR00116870840001 | $6,681,753.00 |
This Agreement is entered into between the United States of America, hereinafter called the Government, represented by The Defense Advanced Research Projects Agency (DARPA), and the NRX Defense Systems, Inc (NRx), pursuant to and under United States Federal law. Note that by signing this Agreement, *NRX Defense Systems, Inc. *also attests to the accuracy and completion of the Certifications of the Agreement herein Attachment 8, Certifications for Agreement.
| FOR NRX Defense Systems, Inc. | FOR THE GOVERNMENT DEFENSE ADVANCED RESEARCH PROJECTS AGENCY | |||
| (Signature) | (Signature) | |||
| (Name, Title) | (Date) | (Name, Title) | (Date) |
[***] represents redacted information.
TABLE OF CONTENTS
ARTICLES
| ARTICLE I | Scope of the Agreement |
| ARTICLE II | Term |
| ARTICLE III | Management of the Project |
| ARTICLE IV | Agreement Administration |
| ARTICLE V | Obligation and Payment |
| ARTICLE VI | Disputes |
| ARTICLE VII | Patent Rights |
| ARTICLE VIII | Data Rights |
| ARTICLE IX | Foreign Access to Technology |
| ARTICLE X | Safeguarding Covered Defense Information and Cyber Incident Reporting |
| ARTICLE XI | Title to and Disposition of Property |
| ARTICLE XII | Civil Rights Act |
| ARTICLE XIII | Execution |
| ARTICLE XIV | Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment |
| ARTICLE XV | Cybersecurity Maturity Model Certification (CMMC) |
| ARTICLE XVI | Cyber Incident Reporting and Public Release |
| ARTICLE XVII | Protection of Human Subjects |
ATTACHMENTS
| ATTACHMENT 1 | Task Description Document (TDD) |
| ATTACHMENT 2 | Report Requirements |
| ATTACHMENT 3 | Schedule of Milestones and Payments |
| ATTACHMENT 4 | Agreements Officer’s Representative Appointment Memo |
| ATTACHMENT 5 | Certifications for Agreement |
| ATTACHMENT 6 | IP Assertions |
[***] represents redacted information.
ARTICLE I: SCOPE OF THE AGREEMENT
A. Background
The purpose of this agreement is to conduct research for the "Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS)" project. The goal is to conduct a pivotal, 240-patient, randomized controlled trial to establish the first validated single-day treatment for treatment-resistant depression (TRD). The project combines ultra-accelerated transcranial magnetic stimulation (uaTMS) with the drug NRX-101 (a combination of D-cycloserine and lurasidone) to prime synaptic plasticity.
Current treatments for TRD, such as SSRIs, SNRIs, and conventional daily TMS, are limited. They require weeks of daily outpatient treatment, have modest response rates of 30-50%, and are not easily deployable in operational military settings. While some accelerated TMS protocols exist, there is no approved single-day treatment that provides a rapid and durable response. Furthermore, no existing treatments have leveraged the synergistic effect of combining TMS with a pharmacological agent that enhances its mechanism of action in a large-scale, FDA-pivotal trial.
This program is a "critical technology" effort because it addresses the urgent need for a rapid, durable, and deployable treatment for depression and suicidality among military personnel. A successful trial will:
| ● | Provide a treatment that significantly reduces time away from duty (from weeks or months to a single day). |
| ● | Validate a biomarker suite (using TMS-EEG and fMRI) to enable precision "return-to-duty" determinations. |
| ● | Revolutionize the treatment of TRD by providing a new, more effective intervention. |
Current TRD treatments are insufficient because they:
| ● | Lack Speed and Durability: They require long treatment periods and do not offer a rapid and lasting solution. |
| ● | Are Operationally Undeployable: The multi-week protocols are impractical for active-duty military personnel. |
| ● | Lack Precision: There are no validated biomarkers to predict treatment response or to objectively determine when a service member is fit to return to duty. |
| ● | Are Less Effective: Prior approaches have not effectively combined TMS with pharmacological agents to enhance its therapeutic effects on synaptic plasticity. |
Government support, specifically from DARPA, is necessary because this project aligns with national security interests by addressing the significant impact of depression and suicidality on military readiness. DARPA's investment enables a high-risk, high-reward research program that industry alone might not undertake. This support will fund a large-scale, pivotal clinical trial necessary for FDA approval, which is a costly and complex process. This will accelerate the transition of this critical technology to military and veteran healthcare systems.
The issues of particular importance to DARPA addressed in this proposal are:
| ● | Rapid Treatment: Developing a single-day intervention to minimize time away from duty for military personnel. |
| ● | Biomarker Validation: Creating objective, validated biomarkers to guide "return-to-duty" decisions. |
[***] represents redacted information.
| ● | Durability and Efficacy: Establishing a treatment that provides a long-lasting, robust antidepressant effect. |
| ● | Mechanism of Action: Gaining a deeper, mechanistic understanding of how this combination therapy works. |
The dual-use applications for this technology are extensive:
| ● | Military: A deployable, single-day treatment for TRD that can be used in military hospitals and clinics, reducing the impact of depression and suicidality on force readiness. |
| ● | Commercial (Civilian): A widely accessible, lower-burden outpatient alternative to current multi-week TMS protocols for the general population. It can also be applied to veterans through the VA healthcare system. |
The technology targets treatment-resistant depression, a condition with a substantial patient population in both military and civilian sectors. The "nearly universally accessible" nature of a validated one-day TMS treatment suggests a large potential for adoption, aiming to change the standard of care. The primary commercialization goal is to gain FDA approval for NRX-101 as the first pharmacologic agent to be used as an adjunct to TMS. The transition plan targets three main channels:
| ● | Department of Defense (DoD) military treatment facilities. |
| ● | Department of Veterans Affairs (VA) outpatient care. |
| ● | Civilian TMS clinics. |
If the program is successful, the immediate next step is to use the data to seek FDA approval for the combined therapy. This will fundamentally change the standard of care for TRD. Following this, the plan is to transition the regulated drug-device protocol to DoD, VA, and civilian clinics for broad adoption. Further post-approval studies and real-world outcome registries will be used to answer long-term questions about durability and the potential need for retreatment.
B. Definitions
In this Agreement, the following definitions apply:
Agreement: The body of this Agreement and Attachments 1 – 6, which are expressly incorporated in and made a part of the Agreement.
Data: Recorded information, regardless of form or method of recording, which includes but is not limited to, technical data, software, maskworks and trade secrets. The term does not include financial, administrative, cost, pricing or management information and does not include subject inventions, included in Article VII.
Foreign Firm or Institution: A firm or institution organized or existing under the laws of a country other than the United States, its territories, or possessions. The term includes, for purposes of this Agreement, any agency or instrumentality of a foreign government; and firms, institutions or business organizations which are owned or substantially controlled by foreign governments, firms, institutions, or individuals.
Government: The United States of America, as represented by DARPA.
[***] represents redacted information.
Government Purpose Rights: The rights to use, duplicate, or disclose Data, in whole or in part and in any manner, for Government purposes only, and to have or permit others to do so for Government purposes only.
Invention: Any invention or discovery which is or may be patentable or otherwise protectable under Title 35 of the United States Code.
Know-How: All information including, but not limited to discoveries, formulas, materials, inventions, processes, ideas, approaches, concepts, techniques, methods, software, programs, documentation, procedures, firmware, hardware, technical data, specifications, devices, apparatus and machines.
Limited Rights: Rights to use, modify, reproduce, release, perform, display, or disclose Data, in whole or in part, within the Government.
Made: Any invention means the conception or first actual reduction to practice of such invention.
Party: Includes the Government (represented by DARPA), or the Performer, or both.
Performer: NRX Defense Systems, Inc.
Practical application: To manufacture, in the case of a composition of product; to practice, in the case of a process or method, or to operate, in the case of a machine or system; and, in each case, under such conditions as to establish that the invention is capable of being utilized and that its benefits are, to the extent permitted by law or Government regulations, available to the public on reasonable terms.
Program: Research and development being conducted by the Performer, as set forth in Article I, Paragraph C.
Property: Any tangible personal property other than property actually consumed during the execution of work under this agreement.
Subject invention: Any invention conceived or first actually reduced to practice in the performance of work under this Agreement.
Technology: Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.
Unlimited Rights: Rights to use, duplicate, release, or disclose, Data in whole or in part, in any manner and for any purposes whatsoever, and to have or permit others to do so.
Restricted Rights: The Government obtains restricted rights in other than commercial computer
software, required to be delivered or otherwise provided to the Government, that was developed
exclusively at private expense.
C. Scope
1. The Performer shall perform a coordinated research and development program (“Program”) designed to develop Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS). The research shall be carried out in accordance with the Task Description Document (“TDD”) incorporated in this Agreement as Attachment 1. The Performer shall submit or otherwise provide all documentation required by Attachment 2, Report Requirements.
[***] represents redacted information.
2. The Performer shall be paid a pre-established amount for each milestone accomplished in accordance with the Schedule of Milestones and Payments set forth in Attachment 3 and the procedures of Article V. The Schedule of Milestones and Payments may be revised or updated in accordance with Article III.
D. Goals/Objectives
1. The goal of this Agreement is to establish the first validated single-day intervention for treatment-resistant depression (TRD) combining ultra-accelerated TMS (uaTMS: 20 iTBS sessions in one day) with NRX-101 (D-cycloserine + lurasidone) to pharmacologically prime stimulation-induced synaptic plasticity. The program’s primary goal is to determine whether active TMS + NRX-101 produces superior antidepressant effects compared to active TMS + placebo and sham TMS + NRX-101 in a 240-subject, 3-arm triple-blind RCT, while validating a biomarker suite (TMS-EEG and fMRI) that can support objective return-to-duty determination and underlying mechanism of action.
2. The Government will have continuous involvement with the Performer. The Government will also obtain access to research results and certain rights in patents and data pursuant to Articles VII and VIII. DARPA and the Performer are bound to each other by a duty of good faith and best research effort in achieving the goals of the Program.
3. This Agreement is an “other transaction” pursuant to 10 U.S.C. § 4021. The Parties agree that the principal purpose of this Agreement is for the Government and the Performer to provide for a coordinated effort to advance research and technology goals of the program and not primarily for the acquisition of property or services for the direct benefit or use of the Government. This Agreement is not intended to be, nor shall it be construed as, by implication or otherwise, a partnership, a corporation, or other business organization.
ARTICLE II: TERM
A. Term of this Agreement
The Program commences upon the date of the last signature hereon and continues for eighteen (18) months. Provisions of this Agreement, which, by their express terms or by necessary implication, apply for periods of time other than specified herein, shall be given effect, notwithstanding this Article.
B. Termination Provisions
Subject to a reasonable determination that the program will not produce beneficial results, either Party may terminate this Agreement by written notice to the other Party, provided that such written notice is preceded by consultation between the Parties. In the event of a termination of the Agreement, it is agreed that disposition of Data developed under this Agreement, shall be in accordance with the provisions set forth in Article VIII, Data Rights. The Government and the Performer will negotiate in good faith a reasonable and timely adjustment of all outstanding issues between the Parties as a result of termination. Failure of the Parties to agree to a reasonable adjustment will be resolved pursuant to Article VI, Disputes. The Government has no obligation to pay the Performer beyond the last completed and paid milestone if the Performer decides to terminate.
[***] represents redacted information.
C. Extending the Term
The Parties may extend by mutual written agreement the term of this Agreement if research opportunities within the vision statement set forth in Article I reasonably warrant. Any extension shall be formalized through modification of the Agreement by the Agreements Officer (“AO”) and the Performer’s Administrator.
ARTICLE III: ** MANAGEMENT OF THE PROJECT **
A. Management and Program Structure
The Performer shall be responsible for the overall technical and program management of the Program, and technical planning and execution shall remain with the Performer. The DARPA Agreements Officer’s Representative (“AOR”) shall provide recommendations to Program developments and technical collaboration and be responsible for the review and verification of milestones.
B. Program Management Planning Process
Program planning will consist of an Annual Program Plan with inputs and reviews from the Performer and DARPA management, containing a detailed schedule of research activities and milestones.
1. Initial Program Plan: The Performer will follow the initial program plan that is contained in the TDD (Attachment 1), and the Schedule of Milestones and Payments (Attachment 3).
2. Overall Program Plan Annual Review
(a) The Performer, with DARPA PM participation and review, will prepare an overall Annual Program Plan in the first quarter of each Agreement year. (For this purpose, each consecutive twelve (12) month period from (and including) the month of execution of this Agreement during which this Agreement shall remain in effect shall be considered an “Agreement Year”). The Annual Program Plan may be presented and reviewed at an annual site review, at the discretion of the DARPA PM, which will be attended by the Performer’s Management, the DARPA AOR, Senior DARPA management or other DARPA program managers and personnel as appropriate. The Performer, with DARPA participation and review, will prepare a final Annual Program Plan.
(b) The Annual Program Plan provides a detailed schedule of research activities, commits the Performer to meet specific performance objectives and describes the milestones. The Annual Program Plan will consolidate all prior adjustments in the research schedule, including revisions/modifications to prospective milestones. Recommendations for changes and technical revisions or modifications to the Agreement which result from the Annual Review shall be made in accordance with the provisions of Article III, Paragraph C.
C. Modifications
1. As a result of meetings, annual reviews, or at any time during the term of the Agreement, research progress or results may indicate that a change in the TDD would be beneficial to program objectives. Recommendations for modifications, including justifications to support any changes to the TDD and prospective milestones, will be documented and submitted by the Performer to the DARPA PM and AOR with a copy to the DARPA AO. This documentation will detail the technical, chronological, and financial impact of the proposed modification to the research program. The Performer shall approve any Agreement modification. The Government is not obligated to pay for additional or revised future milestones until the Schedule of Milestones and Payments (Attachment 3) is formally revised by the DARPA AO and made part of this Agreement.
[***] represents redacted information.
2. The DARPA AOR shall be responsible for the review and verification of any recommendations to revise or otherwise modify the Agreement TDD, Schedule of Milestones and Payments, or other proposed changes to the terms and conditions of this Agreement.
3. For minor or administrative Agreement modifications (e.g. changes in the paying office or appropriation data, changes to Government or the Performer’s personnel identified in the Agreement, etc.) no signature is required by the Performer.
ARTICLE IV: AGREEMENT ADMINISTRATION
Unless otherwise provided in this Agreement, approvals permitted or required to be made by DARPA may be made only by the DARPA AO. Administrative and contractual matters under this Agreement shall be referred to the following representatives of the parties:
A. Government Points of Contact:
Agreements Officer (AO):
Lydia Richards
Agreements Officer
[***]
[***]
DARPA Program Manager (PM):
Robin Bonomi
Program Manager
[***]
[***]
Agreements Officer’s Representative (AOR):
Matthew Riedy
Agreements Officer Representative
[***]
[***]
B. Performer’s Points of Contact
Administrative/Contracting:
Dennis Guevara
Study Coordinator
[***]
[***]
Program Manager:
Jonathan C. Javitt, M.D.
[***]
[***]
[***] represents redacted information.
ARTICLE V: OBLIGATION AND PAYMENT
A. Obligation
The Government’s liability to make payments to the Performer is limited to only those funds obligated under this Agreement or by modification to the Agreement. DARPA may incrementally fund this Agreement.
B. Payments
1. The Parties agree that pre-established payments will be made for the completion of milestones. These payments reflect advanced payments and value received by the Government toward the accomplishment of the research goals of this Agreement.
2. The Performer has and agrees to maintain an established accounting system which complies with Generally Accepted Accounting Principles and with the requirements of this Agreement
3. The Performer shall document the accomplishments of each milestone by submitting or otherwise providing the Milestones Report required by Attachment 2, Part E. To the maximum extent practicable, the DARPA AOR shall review the deliverable(s)/milestone report(s) and either: 1) provide a written notice of rejection to the Performer which includes feedback regarding deficiencies requiring correction, or 2) written notice of acceptance to the DARPA PM, AO, and Performer within fifteen (15) calendar days of receipt of deliverable(s)/milestone report(s). Upon written approval from the DARPA AOR, the Performer will submit their invoice through Wide Area Workflow (WAWF), as detailed below.
4. Payments will be made by the Defense Agency Financial Services office, as indicated below, within thirty (30) calendar days of an accepted invoice in WAWF. WAWF is a secure web-based system for electronic invoicing, receipt and acceptance. The WAWF application enables electronic form submission of invoices, government inspection, and acceptance documents in order to support DoD’s goal of moving to a paperless acquisition process. Authorized DoD users are notified of pending actions by e-mail and are presented with a collection of documents required to process the contracting or financial action. It uses Public Key Infrastructure (PKI) to electronically bind the digital signature to provide non-refutable proof that the user (electronically) signed the document with the contents. Benefits include online access and full spectrum view of document status, minimized re-keying and improving data accuracy, eliminating unmatched disbursements and making all documentation required for payment easily accessible.
5. The Performer is required to utilize the WAWF system when processing invoices and receiving reports under this Agreement. The Performer shall (i) ensure an Electronic Business Point of Contact is designated in System for Award Management at http://www.sam.gov and (ii) register to use WAWF–RA at the https://wawf.eb.mil site, within ten (10) calendar days after award of this Agreement. Step by Step procedures to register are available at the https://wawf.eb.mil site. The Performer is directed to use the “2-in-1” format when processing invoices. The Performer shall maintain an active registration for “All Awards” in System for Award Management (SAM) throughout the life of the award. For WAWF Payment and Invoicing Support, email [***] or contact WAWF help desk at [***] or email [***].
| a. | For the Issue By DoDAAC, enter HR0011. |
| b. | For the Admin DoDAAC, enter HR0011. |
| c. | For the Service Acceptor AOR fields, enter N6523. |
| d. | Leave the Inspect by DoDAAC, Ship From Code DoDAAC, Service Approver, and LPO DoDAAC fields blank unless otherwise directed by the Agreements Officer. |
[***] represents redacted information.
| e. | The following guidance is provided for invoicing processed under this Agreement through WAWF: |
| ● | Acceptance within the WAWF system shall be performed by the AOR upon receipt of a confirmation email, or other form of transmittal, from the AOR. |
| ● | The Performer shall upload the AOR approval as an attachment upon submission of an invoice in WAWF. |
| ● | Payments shall be made by DFAS-HQ0339. |
| ● | The Performer agrees, when entering invoices entered in WAWF to utilize the CLINs associated with each milestone as delineated at Attachment 3. The description of the CLIN shall include reference to the associated milestone number along with other necessary descriptive information. The Performer agrees that the Government may reject invoices not submitted in accordance with this provision. |
Note for DFAS: The Agreement shall be entered into the DFAS system by CLIN –** Milestone association (MS)/ACRN as delineated at Attachment 3. The Agreement is to be paid out by CLIN (MS)/ACRN. Payments shall be made using the CLIN (MS)/ACRN association as delineated at Attachment 3. **
| f. | Payee Information: As identified at the System for Award Management. |
| ● | Cage Code: [***] |
| ● | SAM UEI: [***] |
| ● | TIN: [***] |
6. Payments shall be made in the amounts set forth in Attachment 3, provided the DARPA AOR has verified the accomplishment of the milestones.
7. Government funds shall be maintained in an interest-bearing account prior to disbursement. This account shall not be in U. S. Treasury Notes. Any interest earned shall be remitted annually to the DARPA AO, or designee. Interest payments shall be made payable to the U. S. Treasury. Interest amounts less than One Thousand Dollars ($1,000.00) per year may be retained for administrative expenses.
8. Limitation of Funds: In no case shall the Government’s financial liability exceed the amount obligated under this Agreement.
9. Payments shall be made in the amounts set forth in Attachment 3, provided the DARPA AOR has verified the accomplishment of the milestone. It is recognized that the quarterly accounting of current expenditures reported in the “Business Status Report” submitted in accordance with Attachment 2 is not necessarily intended or required to match the milestones until submission of the Final Report; however, milestones shall be revised, within the negotiated fixed ceiling price, during the course of the program to reflect current and revised projected expenditures.
10. Financial Records and Reports: The Performer shall maintain adequate records to account for all funding under this Agreement. Upon completion or termination of this Agreement, whichever occurs earlier, the Performer shall furnish a copy of the Final Report required by Attachment 2, Part F. The Performer’s relevant financial records are subject to examination or audit on behalf of DARPA by the Government for a period not to exceed three (3) years after expiration of the term of this Agreement. The AO or designee shall have direct access to sufficient records and information of the Performer, to ensure full accountability for all funding under this Agreement. Such audit, examination, or access shall be performed during business hours on business days upon prior written notice and shall be subject to the security requirements of the audited party.
[***] represents redacted information.
ARTICLE VI: DISPUTES
A. General
The Parties shall communicate with one another in good faith and in a timely and cooperative manner when raising issues under this Article.
B. Dispute Resolution Procedures
1. Any disagreement, claim or dispute between DARPA and the Performer concerning questions of fact or law arising from or in connection with this Agreement, and, whether or not involving an alleged breach of this Agreement, may be raised only under this Article.
2. Whenever disputes, disagreements, or misunderstandings arise, the Parties shall attempt to resolve the issue(s) involved by discussion and mutual agreement as soon as practicable. In no event shall a dispute, disagreement or misunderstanding which arose more than three (3) months prior to the notification made under Subparagraph B.3 of this Article constitute the basis for relief under this Article unless the Director of DARPA in the interests of justice waives this requirement.
3. Failing resolution by mutual agreement, the aggrieved Party shall document the dispute, disagreement, or misunderstanding by notifying the other Party (through the DARPA AO or the Performer’s Administrator, as the case may be) in writing of the relevant facts, identify unresolved issues, and specify the clarification or remedy sought. Within five (5) working days after providing notice to the other Party, the aggrieved Party may, in writing, request a joint decision by the DARPA Senior Procurement Executive, and Chief Operating Officer of NRx Defense Systems, Inc., who is appointed by the Performer. The other Party shall submit a written position on the matter(s) in dispute within thirty (30) calendar days after being notified that a decision has been requested. DARPA Senior Procurement Executive, and the senior executive shall conduct a review of the matter(s) in dispute and render a decision in writing within thirty (30) calendar days of receipt of such written position. Any such joint decision is final and binding.
4. In the absence of a joint decision, upon written request to the Deputy Director of DARPA, made within thirty (30) calendar days of the expiration of the time for a decision under Subparagraph B.3 above, the dispute shall be further reviewed. The Deputy Director of DARPA may elect to conduct this review personally or through a designee or jointly with the CEO of NRx Pharmaceuticals, who is appointed by the Performer. Following the review, the Deputy Director of DARPA or designee will resolve the issue(s) and notify the Parties in writing. Such resolution is not subject to further administrative review by the Director of DARPA, whose decision to the extent permitted by law shall be final and binding.
C. Limitation of Damages
Claims for damages of any nature whatsoever pursued under this Agreement shall be limited to direct damages only up to the aggregate amount of DARPA funding disbursed as of the time the dispute arises. In no event shall DARPA be liable for claims for consequential, punitive, special and incidental damages, claims for lost profits, or other indirect damages. In no event shall the Performer be liable for claims for consequential, punitive, special and incidental damages, claims for lost profits, or other indirect damages, except in cases of willful misconduct by the Performer.
[***] represents redacted information.
ARTICLE VII: PATENT RIGHTS
A. Allocation of Principal Rights
1. Unless the Performer shall have notified DARPA, in accordance with Subparagraph B.2 below, that the Performer does not intend to retain title, the Performer shall retain the entire right, title, and interest throughout the world to each subject invention consistent with the provisions of this Article.
2. With respect to any subject invention in which the Performer retains title, DARPA shall have a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the United States the subject invention throughout the world.
B. Invention Disclosure, Election of Title, and Filing of Patent Application
1. The Performer shall disclose each subject invention to DARPA within four (4) months after the inventor discloses it in writing to their company personnel responsible for patent matters. The disclosure to DARPA shall be in the form of a written report and shall identify the Agreement and circumstances under which the invention was made and the identity of the inventor(s). It shall be sufficiently complete in technical detail to convey a clear understanding, to the extent known at the time of the disclosure, of the nature, purpose, operation, and the physical, chemical, biological, or electrical characteristics of the Invention. The disclosure shall also identify any publication, sale, or public use of the invention and whether a manuscript describing the invention has been submitted and/or accepted for publication at the time of disclosure.
2. If the Performer determines that it does not intend to retain title to any such Invention, the Performer shall notify DARPA, in writing, within eight (8) months of disclosure to DARPA. However, in any case where publication, sale, or public use has initiated the one (1)-year statutory period wherein valid patent protection can still be obtained in the United States, the period for such notice may be shortened by DARPA to a date that is no more than sixty (60) calendar days prior to the end of the statutory period.
3. The Performer shall file its initial patent application on a subject invention to which it elects to retain title within one (1) year after election of title or, if earlier, prior to the end of the statutory period wherein valid patent protection can be obtained in the United States after a publication, or sale, or public use. The Performer may elect to file patent applications in additional countries (including the European Patent Office and the Patent Cooperation Treaty) within either ten (10) months of the corresponding initial patent application or six (6) months from the date permission is granted by the Commissioner of Patents and Trademarks to file foreign patent applications, where such filing has been prohibited by a Secrecy Order.
4. The Performer shall notify DARPA of any decisions not to continue the prosecution of a patent application, pay maintenance fees, or defend in a reexamination or opposition proceedings on a patent, in any country, not less than thirty (30) calendar days before the expiration of the response period required by the relevant patent office.
[***] represents redacted information.
5. Requests for extension of the time for disclosure election, and filing under this Article, may be granted at DARPA’s discretion after considering the circumstances of the Performer and the overall effect of the extension.
6. The Performer shall submit to DARPA annual listings of subject inventions. At the completion of the Agreement, the Performer shall submit a comprehensive listing of all subject inventions identified during the course of the Agreement and the current status of each.
C. Conditions When the Government May Obtain Title
Upon DARPA’s written request, the Performer shall convey title to any subject invention to DARPA under any of the following conditions:
1. If the Performer fails to disclose or elects not to retain title to the subject invention within the times specified in Paragraph B of this Article; however, DARPA may only request title within sixty (60) calendar days after learning of the failure of the Performer to disclose or elect within the specified times;
2. In those countries in which the Performer fails to file patent applications within the times specified in Paragraph B of this Article; however, if the Performer has filed a patent application in a country after the times specified in Paragraph B of this Article, but prior to its receipt of the written request by DARPA, the Performer shall continue to retain title in that country; or
3. In any country in which the Performer decides not to continue the prosecution of any application for, to pay the maintenance fees on, or defend in reexamination or opposition proceedings on, a patent on a subject invention.
D. Minimum Rights to the Performer and Protection of the Performer’s Right to File
1. The Performer shall retain a nonexclusive, royalty-free license throughout the world in each subject invention to which the Government obtains title, except if the Performer fails to disclose the subject invention within the times specified in Paragraph B of this Article. The Performer’s license extends to its domestic (including Canada) subsidiaries and affiliates, if any, and includes the right to grant licenses of the same scope to the extent that the Performer was legally obligated to do so at the time the Agreement was awarded. The license is transferable only with the approval of DARPA, except when transferred to the successor of that part of the business to which the subject invention pertains. DARPA approval for license transfer shall not be unreasonably withheld.
2. The Performer’s domestic license may be revoked or modified by DARPA to the extent necessary to achieve expeditious practical application of the Subject Invention pursuant to an application for an exclusive license submitted consistent with appropriate provisions at 37 CFR Part 404. This license shall not be revoked in that field of use or the geographical areas in which the Performer has achieved practical application and continues to make the benefits of the subject invention reasonably accessible to the public. The license in any foreign country may be revoked or modified at the discretion of DARPA to the extent the Performer, its licensees, or the subsidiaries or affiliates have failed to achieve practical application in that foreign country.
3. Before revocation or modification of the license, DARPA shall furnish the Performer a written notice of its intention to revoke or modify the license, and the Performer shall be allowed thirty (30) calendar days (or such other time as may be authorized for good cause shown) after the notice to show cause why the license should not be revoked or modified.
[***] represents redacted information.
E. Action to Protect the Government’s Interest
1. The Performer agrees to execute or to have executed and promptly deliver to DARPA all instruments necessary to (i) establish or confirm the rights the Government has throughout the world in those subject inventions to which the Performer elects to retain title, and (ii) convey title to DARPA when requested under Paragraph C of this Article and to enable the Government to obtain patent protection throughout the world in that subject invention.
2. The Performer agrees to require by written agreement with its employees, other than clerical and non-technical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent matters and in a format suggested by the Performer each subject invention made under this Agreement in order that the Performer can comply with the disclosure provisions of Paragraph B of this Article. The Performer shall instruct employees, through employee agreements or other suitable educational programs, on the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U. S. or foreign statutory bars.
3. The Performer shall include, within the specification of any United States patent application and any patent issuing thereon covering a subject invention, the following statement:
This invention was made with Government support under Agreement No. HR0011-26-3-E138, awarded by DARPA. The Government has certain rights in the invention.
F. Lower Tier Agreements
The Performer shall include this Article, suitably modified, in all subcontracts or lower tier agreements, regardless of tier, for experimental, developmental, or research work.
G. Reporting on Utilization of Subject Inventions
1. The Performer agrees to submit, during the term of the Agreement, an annual report on the utilization of a subject invention or on efforts at obtaining such utilization that are being made by the Performer or its licensees or assignees. Such reports shall include information regarding the status of development, date of first commercial sale or use, gross royalties received by the Performer, and such other data and information as the agency may reasonably specify. The Performer also agrees to provide additional reports as may be requested by DARPA in connection with any march-in proceedings undertaken by DARPA in accordance with Paragraph I of this Article. DARPA agrees it shall not disclose such information to persons outside the Government without permission of the Performer, unless required by law.
2. All required reporting shall be accomplished, to the extent possible, using the i-Edison reporting website: https://www.nist.gov/iedison. To the extent any such reporting cannot be carried out by use of i-Edison, reports and communications shall be submitted to the Agreements Officer and Administrative Agreements Officer.
H. Preference for American Industry
Notwithstanding any other provision of this clause, the Performer agrees that it shall not grant to any person the exclusive right to use or sell any subject invention in the United States unless such person agrees that any product embodying the subject invention or produced through the use of the subject invention shall be manufactured substantially in the United States. However, in individual cases, the requirements for such an agreement may be waived by DARPA upon a showing by the Performer that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that, under the circumstances, domestic manufacture is not commercially feasible.
[***] represents redacted information.
I. March-in Rights
The Performer agrees that, with respect to any subject invention in which it has retained title, DARPA has the right to require the Performer, an assignee, or exclusive licensee of a subject invention to grant a non-exclusive license to a responsible applicant or applicants, upon terms that are reasonable under the circumstances, and if the Performer, assignee, or exclusive licensee refuses such a request, DARPA has the right to grant such a license itself if DARPA determines that:
1. Such action is necessary because the Performer or assignee has not taken effective steps, consistent with the intent of this Agreement, to achieve practical application of the subject invention;
2. Such action is necessary to alleviate health or safety needs which are not reasonably satisfied by the Performer, assignee, or their licensees;
3. Such action is necessary to meet requirements for public use and such requirements are not reasonably satisfied by the Performer, assignee, or licensees; or
4. Such action is necessary because the agreement required by Paragraph (H) of this Article has not been obtained or waived or because a licensee of the exclusive right to use or sell any subject invention in the United States is in breach of such Agreement.
ARTICLE VIII: DATA RIGHTS
A. Allocation of Principal Rights
1. The Parties agree that in consideration for Government funding, the Performer intends to reduce to practical application items, components and processes developed under this Agreement.
2. With respect to Data developed or generated under this Agreement related to the program, the Government shall receive unlimited rights, as defined in Article I, Paragraph B except with respect to the data rights and patent rights assertions described in detail in Attachment 6 of this Agreement.
3. With respect to Data delivered pursuant to Attachment 2 under the Agreement, the Government shall receive unlimited rights with the exception of the data listed in Attachment 6. Notwithstanding the provision in A.4, the performer agrees, with respect to data generated or developed under this Agreement, the Government may, within 3 years after completion or termination of this Agreement, require delivery of data and receive unlimited rights except for the data contained in Attachment 6 which will be subject to the rights asserted in that Attachment.
4. March-In Rights
(a) In the event the Government chooses to exercise its March-in Rights, as defined in Article VII, Paragraph I of this Agreement, the Performer agrees, upon written request from the Government, to deliver at no additional cost to the Government, all Data necessary to achieve practical application within sixty (60) calendar days from the date of the written request. The Government shall retain Unlimited Rights, as defined in Article I, Paragraph B of this Agreement, to this delivered Data.
[***] represents redacted information.
(b) To facilitate any potential deliveries, the Performer agrees to retain and maintain in good condition until 3 years after completion or termination of this Agreement, all Data necessary to achieve practical application of any subject invention as defined in Article I, Paragraph B of this Agreement.
B. Marking of Data
Pursuant to Paragraph B above, any Data delivered under this Agreement shall be marked with the following legend:
Use, duplication, or disclosure is subject to the restrictions as stated in Agreement HR0011-26-3-E138 between the Government and the Performer.
C. Lower Tier Agreements
The Performer shall include this Article, suitably modified to identify the Parties, in all subcontracts or lower tier agreements, regardless of tier, for experimental, developmental, or research work.
ARTICLE IX: FOREIGN ACCESS TO TECHNOLOGY
This Article shall remain in effect during the term of the Agreement and for three (3) years thereafter.
A. General
The Parties agree that research findings and technology developments arising under this Agreement may constitute a significant enhancement to the national defense, and to the economic vitality of the United States. Accordingly, access to important technology developments under this Agreement by Foreign Firms or Institutions must be carefully controlled. The controls contemplated in this Article are in addition to, and are not intended to change or supersede, the provisions of the International Traffic in Arms Regulations (22 C.F.R. Part 120, et seq.), National Industrial Security Program Operating Manual (NISPOM) (32 C.F.R. Part 117, et seq.), and the Department of Commerce’s Export Administration Regulations (15 C.F.R. Part 730, et seq.).
B. Restrictions on Sale or Transfer of Technology to Foreign Firms or Institutions
1. In order to promote the national security interests of the United States and to effectuate the policies that underlie the regulations cited above, the procedures stated in Subparagraphs C.2, C.3, and C.4 below shall apply to any transfer of Technology. For purposes of this Paragraph, a transfer includes a sale of the company, and sales or licensing of Technology. Transfers do not include:
(a) sales of products or components, or
(b) licenses of software or documentation related to sales of products or components, or
(c) transfer to foreign subsidiaries of the Performer for purposes related to this Agreement, or
[***] represents redacted information.
(d) transfer which provides access to Technology to a Foreign Firm or Institution which is an approved source of supply or source for the conduct of research under this Agreement provided that such transfer shall be limited to that necessary to allow the firm or institution to perform its approved role under this Agreement.
2. The Performer shall provide timely notice to DARPA of any proposed transfers from the Performer of Technology developed under this Agreement to Foreign Firms or Institutions. If DARPA determines that the transfer may have adverse consequences to the national security interests of the United States, the Performer, its vendors, and DARPA shall jointly endeavor to find alternatives to the proposed transfer which obviate or mitigate potential adverse consequences of the transfer but which provide substantially equivalent benefits to the Performer.
3. In any event, the Performer shall provide written notice to the DARPA AOR and AO of any proposed transfer to a foreign firm or institution at least sixty (60) calendar days prior to the proposed date of transfer. Such notice shall cite this Article and shall state specifically what is to be transferred and the general terms of the transfer. Within thirty (30) calendar days of receipt of the Performer’s written notification, the DARPA AO shall advise the Performer whether it consents to the proposed transfer. In cases where DARPA does not concur or sixty (60) calendar days after receipt and DARPA provides no decision, the Performer may utilize the procedures under Article VI, Disputes. No transfer shall take place until a decision is rendered.
4. In the event a transfer of Technology to Foreign Firms or Institutions which is NOT approved by DARPA takes place, the Performer shall (a) refund to DARPA funds paid for the development of the Technology and (b) the Government shall have a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the United States the Technology throughout the world for Government an any and all other purposes, particularly to effectuate the intent of this Agreement. Upon request of the Government, the Performer shall provide written confirmation of such licenses.
C. Lower Tier Agreements
The Performer shall include this Article, suitably modified, to identify the Parties, in all subcontracts or lower tier agreements, regardless of tier, for experimental, developmental, or research work.
ARTICLE X: SAFEGUARDING COVERED DEFENSE INFORMATION AND CYBER INCIDENT REPORTING
| A. | Background |
Protection of Covered Defense Information (CDI), to include Controlled Unclassified Information (CUI) and Controlled Technical Information (CTI), is of paramount importance to DARPA and can directly impact the ability of DARPA to successfully conduct its mission. Therefore, this Article requires the performer to protect CDI that resides on the performer’s information systems. This Article also requires the performer to rapidly report any cyber incident involving CDI.
| B. | Safeguarding CDI |
The performer shall implement the version of NIST Special Publication (SP) 800-171 in effect at the time the solicitation is issued or as authorized by the Agreements Officer for CUI and CTI that resides on the performer’s information systems. Consistent with NIST SP 800-171, implementation may be tailored to facilitate equivalent safeguarding measures used in the performer systems and organization. Any suspected loss or compromise of CDI that resides on the performer’s information systems shall be considered a cyber incident and require the performer to rapidly report the incident to DARPA in accordance with Paragraph C below.
[***] represents redacted information.
| C. | Cyber Incident Reporting |
Upon discovery of a cyber incident involving CUI or CTI, the performer shall take immediate steps to mitigate any further loss or compromise. The performer shall rapidly report the incident to DARPA and provide sufficient details of the event—including identification of detected and isolated malicious software—to enable DARPA to assess the situation and provide feedback to the performer regarding further reporting and potential mitigation actions. The performer shall preserve and protect images of all known affected information systems and all relevant monitoring/packet capture data for at least 90 days from reporting the cyber incident to enable DARPA to assess the cyber incident. The performer agrees to rapidly implement security measures as recommended by DARPA and to provide to DARPA any additionally requested information to help the Parties resolve the cyber incident and to prevent future cyber incidents.
| D. | Public Release |
All information and data covered by this Article must be reviewed and approved by DARPA prior to any public release. The DARPA public release process is governed by DARPA Instruction 65. An online form is available to support those requests at: https://www.darpa.mil/work-with-us/contract-management/public-release
| E. | Lower Tier Agreements |
The performer shall include this Article in all subcontracts or lower tier agreements, regardless of tier, for work performed in support of this Agreement.
| F. | Definitions |
Compromise: Disclosure of information to unauthorized persons, or a violation of the security policy of a system, in which unauthorized intentional or unintentional disclosure, modification, destruction, or loss of an object, or the copying of information to unauthorized media may have occurred.
Covered Contractor Information System: Unclassified information system that is owned, or operated by or for, a contractor and that processes, stores, or transmits covered defense information.
Covered Defense Information (CDI): Unclassified controlled technical information or other information, as described in the Controlled Unclassified Information (CUI) Registry at http://www.archives.gov/cui/registry/category-list.html, that requires safeguarding or dissemination controls pursuant to and consistent with law, regulations, and Governmentwide policies, and is (1) Marked or otherwise identified in the agreement, task order, or delivery order and provided to the performer by or on behalf of DoD in support of the performance of the agreement; or (2) Collected, developed, received, transmitted, used, or stored by or on behalf of the performer in support of the performance of the agreement.
Controlled Technical Information (CTI): Technical information with military or space application that is subject to controls on the access, use, reproduction, modification, performance, display, release, disclosure, or dissemination. Controlled technical information would meet the criteria, if disseminated, for distribution statements B through F using the criteria set forth in DoD Instruction 5230.24, Distribution Statements on Technical Documents.
[***] represents redacted information.
Controlled Unclassified Information (CUI): Unclassified information that requires safeguarding or dissemination controls, pursuant to and consistent with applicable law, regulations, and Government-wide policies. Instructions for the use, marking, dissemination, and storage of CUI can be found in DoD Instruction 5200.48, “Controlled Unclassified Information (CUI).”
Cyber Incident: Actions taken through the use of computer networks that result in a compromise or an actual or potentially adverse effect on an information system and/or the information residing therein.
Information System: A discrete set of information resources organized for the collection, processing, maintenance, use, sharing, dissemination, or disposition of information.
Rapidly Report: Report to DARPA within 72 hours of discovery of any cyber incident.
ARTICLE XI: TITLE TO AND DISPOSITION OF PROPERTY
A. Title to Property
No significant items of property are expected to be acquired under this Agreement. Title to each item of property acquired under this Agreement with an acquisition value of $10,000 or less shall vest in the Performer upon acquisition with no further obligation of the Parties unless otherwise determined by the AO. Should any item of property with an acquisition value greater than $10,000 be required, the Performer shall obtain prior written approval of the AO. Title to this property shall also vest in the Performer upon acquisition. The Performer shall be responsible for the maintenance, repair, protection, and preservation of all property at its own expense.
B. Disposition of Property
At the completion of the term of this Agreement, items of property with an acquisition value greater than $10,000 shall be disposed of in the following manner:
1. Purchased by the Performer at an agreed-upon price, the price to represent fair market value, with the proceeds of the sale being returned to DARPA; or
2. Transferred to a Government research facility with title and ownership being transferred to the Government; or
3. Donated to a mutually agreed University or technical learning center for research purposes; or
4. Any other DARPA-approved disposition procedure.
ARTICLE XII: CIVIL RIGHTS ACT
This Agreement is subject to the compliance requirements of Title VI of the Civil Rights Act of 1964 as amended (42 U.S.C. § 2000d) relating to nondiscrimination in Federally assisted programs. The Performer has signed an Assurance of Compliance with the nondiscriminatory provisions of the Act.
[***] represents redacted information.
ARTICLE XIII: EXECUTION
This Agreement constitutes the entire agreement of the Parties and supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions among the Parties, whether oral or written, with respect to the subject matter hereof. This Agreement may be revised only by written consent of the Performer and the DARPA AO. This Agreement, or modifications thereto, may be executed in counterparts each of which shall be deemed as original, but all of which taken together shall constitute one and the same instrument.
ARTICLE XIV: PROHIBITION ON CERTAIN TELECOMMUNICATIONS AND VIDEO SURVEILLANCE SERVICES OR EQUIPMENT
| A. | ** Definitions** |
Covered Foreign Country: The People’s Republic of China.
Covered Telecommunications Equipment or Services:
(1) Telecommunications equipment produced by Huawei Technologies Company or ZTE Corporation (or any subsidiary or affiliate of such entities);
(2) Video surveillance and telecommunications equipment produced by Hytera Communications Corporation, Hangzhou Hikvision Digital Technology Company, or Dahua Technology Company (or any subsidiary or affiliate of such entities);
(3) Telecommunications or video surveillance services provided by such entities or using such equipment; or
(4) Telecommunications or video surveillance equipment or services produced or provided by an entity that the Secretary of Defense, in consultation with the Director of the National Intelligence or the Director of the Federal Bureau of Investigation, reasonably believes to be an entity owned or controlled by, or otherwise connected to, the government of a Covered Foreign Country.
Critical Technology:
(1) Defense articles or defense services included on the United States Munitions List set forth in the International Traffic in Arms Regulations under subchapter M of chapter I of title 22, Code of Federal Regulations;
(2) Items included on the Commerce Control List set forth in Supplement No. 1 to part 774 of the Export Administration Regulations under subchapter C of chapter VII of title 15, Code of Federal Regulations, and controlled—
(i) Pursuant to multilateral regimes, including for reasons relating to national security, chemical and biological weapons proliferation, nuclear nonproliferation, or missile technology; or
[***] represents redacted information.
(ii) For reasons relating to regional stability or surreptitious listening;
(3) Specially designed and prepared nuclear equipment, parts and components, materials, software, and technology covered by part 810 of title 10, Code of Federal Regulations (relating to assistance to foreign atomic energy activities);
(4) Nuclear facilities, equipment, and material covered by part 110 of title 10, Code of Federal Regulations (relating to export and import of nuclear equipment and material);
(5) Select agents and toxins covered by part 331 of title 7, Code of Federal Regulations, part 121 of title 9 of such Code, or part 73 of title 42 of such Code; or
(6) Emerging and foundational technologies controlled pursuant to Section 1758 of the Export Control Reform Act of 2018 (50 U.S.C. 4817).
| B. | ** Prohibition** |
In accordance with Public Law 115-232, Section 889 (b), the Performer is prohibited from obligating or expending funds received by the Government under this Agreement to:
| 1. | Procure or obtain; |
| 2. | Extend or renew a contract to procure or obtain; or |
| 3. | Enter into a contract (or extend or renew a contract) to procure or obtain equipment, services, or systems that uses Covered Telecommunications Equipment or Services as a substantial component of any system, or as Critical Technology as part of any system. |
| C. | Lower Tier Agreements |
The Performer shall include this Article, suitably modified, in all subcontracts or lower tier agreements.
ARTICLE XV: CYBERSECURITY MATURITY MODEL CERTIFICATION (CMMC)
A. Background
As codified in 32 CFR Part 170, the Cybersecurity Maturity Model Certification (CMMC) Program is designed to ensure Department of Defense (DoD) performers are properly safeguarding Federal Contract Information (FCI) and Controlled Unclassified Information (CUI) that is processed, stored, or transmitted on performer information systems. The CMMC Program provides a consistent methodology to assess a performer's implementation of required cybersecurity requirements. Performers are encouraged to visit the DoD Chief Information Officer CMMC Resources & Documentation site for more information on CMMC: https://dodcio.defense.gov/cmmc/Resources-Documentation/. The information categories used in this Article (FCI and CUI) and in the Cyber Incident Reporting and Public Release Article (CUI, CTI, and CDI) are intended to operate together; the relationship among these categories is described in the Cyber Incident Reporting and Public Release Article.
B. CMMC Level Requirement
(1) The CMMC level required for performance under this Agreement is: CMMC Level 1 (Self), applicable to the information system(s) that will process, store, or transmit FCI in performance of this Agreement.
[***] represents redacted information.
(2) The performer shall not process, store, or transmit FCI or CUI on any information system used in performance of this Agreement unless that system has achieved and maintains a current CMMC status at the level identified in paragraph (1).
(3) The performer shall maintain the required CMMC status for the duration of performance of this Agreement and shall complete and maintain the annual affirmation of continuous compliance in SPRS in accordance with 32 C.F.R. § 170.22.
(4) Plans of Action and Milestones (POA&M): Where the applicable CMMC level permits conditional status, any POA&M shall be closed out within 180 days of the conditional assessment date, consistent with 32 C.F.R. § 170.21. Failure to achieve final status within that period renders the conditional status void.
(5) Failure to Maintain Compliance: Failure to maintain the CMMC status required by this Article, including the failure to close out a POA&M within the required timeframe or maintain a current annual affirmation in SPRS, may be grounds for the Government to, at its sole discretion:
(a) Withhold payments;
(b) Prohibit the performer from processing, storing, or transmitting FCI or CUI under this Agreement until compliance is restored; and/or
(c) Terminate this Agreement for non-compliance.
C. Change in Information Handling Requirements
(1) The CMMC level identified in Paragraph B reflects the information handling requirements anticipated at the time of award. The Parties acknowledge that, in the course of research under this Agreement, the categories of information processed, stored, or transmitted on performer information systems may change, including the introduction of CUI on an information system previously assessed only for FCI.
(2) If the performer determines, reasonably anticipates, or is informed by the PM or AOR that performance will require processing, storing, or transmitting CUI on an information system that does not hold a CMMC status sufficient for CUI, the performer shall promptly notify the Agreements Officer before such CUI is introduced to that system, and shall not process, store, or transmit the CUI on that system until the requirements of this Paragraph are met.
(3) Upon such notification, the Parties shall confer in good faith to determine the appropriate CMMC level, the timeframe for the performer to achieve the required CMMC status, any interim safeguarding or data-handling measures, and any corresponding modification to this Agreement. Any change to the required CMMC level shall be effected by modification of this Agreement.
(4) Pending achievement of the required CMMC status, the performer shall implement interim measures as agreed with the Agreements Officer, which may include deferring CUI-generating activities, segregating or restricting the affected information, or handling the CUI on an alternative information system that holds a sufficient CMMC status.
D. Lower Tier Agreements (Flow-Down)
(1) The performer shall include the substance of this Article in all subawards, subcontracts, and lower-tier agreements, regardless of tier, under which the lower-tier entity will process, store, or transmit FCI or CUI in performance of this Agreement.
(2) The performer shall not award, and shall ensure no lower-tier entity awards, any such instrument to an entity that has not achieved and does not maintain the CMMC status appropriate to the FCI/CUI it will handle, consistent with the flow-down requirements of 32 C.F.R. § 170.23.
(3) The performer remains responsible to DARPA for ensuring lower-tier compliance with this Article.
(4) Verification of Lower-Tier Status: Upon request by the Agreements Officer, the performer shall provide evidence demonstrating how it has verified that its lower-tier entities meet the CMMC requirements flowed down pursuant to this Article. Such evidence may include, for example, confirmation of the subcontractor's status in SPRS.
[***] represents redacted information.
E. Definitions
CMMC (Cybersecurity Maturity Model Certification): The DoD program established under 32 C.F.R. Part 170 that verifies a performer's implementation of cybersecurity requirements through self-assessment or third-party/government assessment, expressed as a CMMC level and status.
CMMC Status: The result of an assessment reflecting the degree to which a performer has implemented the required security requirements at a given CMMC level, as recorded in SPRS.
Controlled Unclassified Information(CUI): Unclassified information the United States
Government creates or possesses that requires safeguarding or dissemination controls
limiting its distribution to those with a lawful government purpose. CUI may not be
released to the public absent further review.
Federal Contract Information (FCI): Information, not intended for public release, that is provided by or generated for the Government under a contractual agreement to develop or deliver a product or service to the Government, but not including information provided by the Government to the public (such as that on public Web sites) or simple transactional information, such as that necessary to process payments.
Plan of Action and Milestones (POA&M): A document that identifies tasks to be accomplished, the resources required to accomplish the elements of the plan, any milestones in meeting the tasks, and scheduled completion dates for the milestones, consistent with 32 C.F.R. § 170.21.
SPRS (Supplier Performance Risk System): The authoritative DoD system of record for posting assessment scores, CMMC results, and affirmations.
ARTICLE XVI: CYBER INCIDENT REPORTING AND PUBLIC RELEASE
A. Background
Protection of Covered Defense Information (CDI), to include Controlled Unclassified Information (CUI) and Controlled Technical Information (CTI), is of paramount importance to DARPA and can directly impact the ability of DARPA to successfully conduct its mission. The cybersecurity safeguarding requirements applicable to information systems used in performance of this Agreement are established in the Cybersecurity Maturity Model Certification Article. This Article addresses the performer's obligations to report and respond to cyber incidents involving CDI, and to control the public release of information under this Agreement.
B. Relationship to Cybersecurity Maturity Certification Article
This Article supplements, and does not replace, the safeguarding requirements established in the Cybersecurity Maturity Model Certification Article. To the extent any provision of this Article addresses the implementation of security requirements for information systems, the requirements of the Cybersecurity Maturity Model Certification Article shall govern. Nothing in this Article relieves the performer of any obligation under that Article.
C. Information Categories
This Agreement uses several related categories of protected information across this Article and the Cybersecurity Maturity Model Certification Article. These categories are intended to operate together, not in conflict, and are understood as follows:
Federal Contract Information (FCI) is information provided by or generated for the Government under this Agreement that is not intended for public release. It is addressed under the Cybersecurity Maturity Model Certification Article.
Controlled Unclassified Information (CUI) is the broader category of unclassified information requiring safeguarding or dissemination controls, and is addressed under both Articles.
[***] represents redacted information.
Controlled Technical Information (CTI) is a subset of CUI consisting of technical information with military or space application subject to dissemination controls (distribution statements B through F).
Covered Defense Information (CDI) is used in this Article as a collective reference to CUI and CTI residing on information systems used in performance of this Agreement.
The cybersecurity safeguarding and certification requirements applicable to FCI and CUI are established in the Cybersecurity Maturity Model Certification Article. The cyber incident reporting and public release requirements of this Article apply to cyber incidents involving CDI (i.e., CUI and CTI). The use of differing category terms between the two Articles does not create separate or conflicting obligations; where the same information falls within more than one category, the requirements of each Article apply concurrently to that information.
D. Cyber Incident Reporting
Any actual or reasonably suspected unauthorized access to, disclosure of, loss of, or compromise of CDI residing on an information system used in performance of this Agreement that could reasonably affect the confidentiality, integrity, or availability of such information, or otherwise affect performance under this Agreement, shall be considered a reportable cyber incident.
Upon discovery of a reportable cyber incident involving CUI or CTI, the Performer shall promptly take reasonable measures to contain, mitigate, and investigate the incident and to prevent any further loss or compromise of CDI. The Performer shall rapidly report the cyber incident to DARPA. The initial report shall include, to the extent known at the time of reporting, the nature of the incident, the date and time of discovery, affected information systems, the categories of CDI potentially affected, known indicators of compromise (including identified malicious software, if applicable), and the containment measures implemented. The Performer shall provide supplemental reports as material information becomes available until the incident has been resolved. The Performer shall preserve and protect forensic evidence relating to the cyber incident, including system images, audit logs, authentication records, relevant monitoring or packet capture data (where available), and other relevant forensic artifacts, for at least ninety (90) days following submission of the initial incident report, or longer if requested by DARPA in support of an ongoing assessment. The Performer shall cooperate with DARPA in assessing the cyber incident and shall provide additional technical information reasonably requested to support the Government's assessment. The Performer shall consider Government recommended mitigation measures in good faith and promptly notify the Agreements Officer of the actions taken or, where applicable, the basis for implementing an alternative mitigation approach.
The Performer shall promptly notify DARPA if the cyber incident materially affects performance under this Agreement, including impacts to technical performance, schedule, cost, or delivery of Agreement milestones, and shall identify planned mitigation measures.
E. Public Release
The Performer shall not publicly release information concerning any cyber incident arising under this Agreement except in accordance with the Public Release Article of this Agreement and DARPA Instruction 65.
F. Lower Tier Agreements
The Performer shall flow down this Article to all subcontractors and lower-tier performers that will receive, generate, access, process, transmit, or store CDI in performance of this Agreement. The Performer remains responsible for ensuring that such lower-tier performers comply with the applicable requirements of this Article.
G. Definitions
Compromise: Disclosure of information to unauthorized persons, or a violation of the security policy of a system, in which unauthorized intentional or unintentional disclosure, modification, destruction, or loss of an object, or the copying of information to unauthorized media may have occurred.
Covered Defense Information (CDI): Unclassified controlled technical information or other information, as described in the Controlled Unclassified Information (CUI) Registry at http://www.archives.gov/cui/registry/category-list.html, that requires safeguarding or dissemination controls pursuant to and consistent with law, regulations, and Governmentwide policies, and is (1) Marked or otherwise identified in the agreement, task order, or delivery order and provided to the performer by or on behalf of the Government in support of the performance of the Agreement; or (2) Collected, developed, received, transmitted, used, or stored by or on behalf of the performer in support of the performance of the Agreement.
[***] represents redacted information.
Controlled Technical Information (CTI): Technical information with military or space application that is subject to controls on the access, use, reproduction, modification, performance, display, release, disclosure, or dissemination. Controlled technical information would meet the criteria, if disseminated, for distribution statements B through F using the criteria set forth in DoD Instruction 5230.24, Distribution Statements on Technical Documents.
Cyber Incident: Actions taken through the use of computer networks that result in a compromise or an actual or potentially adverse effect on an information system and/or the information residing therein.
Information System: A discrete set of information resources organized for the collection, processing, maintenance, use, sharing, dissemination, or disposition of information.
Rapidly Report: Report to DARPA within 72 hours of discovery of any cyber incident.
ARTICLE XVII: ** PROTECTION OF HUMAN SUBJECTS**
a. Definitions. As used in this article—
| 1. | “Assurance of compliance” means a written assurance that an institution will comply with requirements of 32 CFR Part 219, as well as the terms of the assurance, which the Human Research Protection Official determines to be appropriate for the research supported by the Department of Defense (DoD) component (32 CFR 219.103). |
| 2. | “Human Research Protection Official (HRPO)” means the individual designated by the head of the applicable DoD component and identified in the component’s Human Research Protection Management Plan as the official who is responsible for the oversight and execution of the requirements of this Article, although some DoD components may use a different title for this position. |
| 3. | “Human subject” means a living individual about whom an investigator (whether professional or student) conducting research obtains data through intervention or interaction with the individual, or identifiable private information (32 CFR 219.102(e)). For example, this could include the use of human organs, tissue, and body fluids from individually identifiable living human subjects as well as graphic, written, or recorded information derived from individually identifiable living human subjects. |
| 4. | “Institution” means any public or private entity or agency (32 CFR 219.102(b)). |
| 5. | “Institutional Review Board (IRB)” means a board established for the purposes expressed in 32 CFR Part 219 (32 CFR 219.102(g)). |
| 6. | “IRB approval” means the determination of the IRB that the research has been reviewed and may be conducted at an institution within the constraints set forth by the IRB and by other institutional and Federal requirements (32 CFR 219.102(h)). |
| 7. | “Research” means a systematic investigation, including research, development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. Activities that meet this definition constitute research for purposes of 32 CFR Part 219, whether or not they are conducted or supported under a program that is considered research for other purposes. For example, some demonstration and service programs may include research activities (32 CFR 219.102(l)). |
[***] represents redacted information.
b. The Performer shall oversee the execution of the research to ensure compliance with this article. The Performer shall comply fully with 32 CFR Part 219, 10 U.S.C. 980, and, when applicable, Food and Drug Administration policies and regulations.
c. The Performer shall not commence performance of research involving human subjects that is covered under 32 CFR Part 219 or that meets exemption criteria under 32 CFR 219.104, or expend funding on such effort, until and unless the conditions of either the following paragraph (c)(1) or (c)(2) have been met:
| 1. | The Performer furnishes to the HRPO, with a copy to the Agreements Officer, an assurance of compliance and IRB approval and receives notification from the Agreements Officer that the HRPO has approved the assurance as appropriate for the research under the Statement of Work and also that the HRPO has reviewed the protocol and accepted the IRB approval. The Performer may furnish evidence of an existing assurance of compliance for acceptance by the HRPO, if an appropriate assurance has been approved in connection with previous research. The Performer shall notify the Agreements Officer immediately of any suspensions or terminations of the assurance. |
| 2. | The Performer furnishes to the HRPO, with a copy to the Agreements Officer, a determination that the human research proposed meets exemption criteria in 32 CFR 219.104 and receives written notification from the Agreements Officer that the exemption is determined acceptable. The determination shall include citation of the exemption category under 32 CFR 219.104 and a rationale statement. In the event of a disagreement regarding the Performer’s furnished exemption determination, the HRPO retains final judgment on what research activities or classes of research are covered or are exempt under the Agreement. |
d. DoD staff, consultants, and advisory groups may independently review and inspect the Performer’s research and research procedures involving human subjects and based on such findings, DoD may prohibit research that presents unacceptable hazards or otherwise fails to comply with DoD procedures.
e. Failure of the Performer to comply with the requirements of this article will result in the issuance of a stop-work order to immediately suspend, in whole or in part, work and further payment under this Agreement, or will result in other issuance of suspension of work and further payment for as long as determined necessary at the discretion of the Agreements Officer.
f. The Performer shall include the substance of this article, including this paragraph, in all subcontracts/subawards that may include research involving human subjects in accordance with 32 CFR Part 219, and 10 U.S.C. 980, including research that meets exemption criteria under 32 CFR 219.104.
This article does not apply to subcontracts/subawards that involve only the use of cadaver materials.